Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

This systematic review of randomised or pseudorandomised trials was aimed at summarising the effectiveness and safety of artemisinin drugs for treating uncomplicated falciparum malaria. Ninety-three potentially eligible studies were identified and 38 met the inclusion criteria. Most data are from Southeast Asian areas of mefloquine-resistant falciparum malaria, Thailand in particular. Artemisinin drugs achieve high cure rates at follow-up in all endemic areas represented by the studies included provided that the duration of treatment is adequate. Combination with mefloquine improves sustained parasite clearance and is effective in multidrug resistant areas. Provided the dose of both drugs is adequate, the combination can shorten the duration of treatment. There is no evidence from randomised trials that any artemisinin derivative is better than the others. Data from just over 4,300 patients are included for analysis in this review. Despite the large amount of clinical research that has been done, variation in study design, quality and comparisons make synthesis of the data problematic. It is extremely difficult to draw clear conclusions from the existing database.


Journal article


Medecine tropicale : revue du Corps de sante colonial

Publication Date





57 - 58


Liverpool School of Tropical Medicine, United Kingdom.


Humans, Malaria, Falciparum, Sesquiterpenes, Artemisinins, Mefloquine, Antimalarials, Treatment Outcome, Drug Therapy, Combination, Dose-Response Relationship, Drug, Drug Resistance, Research Design, Time Factors, Adult, Child, Randomized Controlled Trials as Topic